ライフサイエンスコーパス: balloon

1 ley catheter (silicone, size 18 F with 30 mL balloon).

2 ffacement of the stenosis by the angioplasty balloon.

3 vessel wall after administration by a coated balloon.

4 echanical performance of the catheter or its balloon.

5 ent poststent dilatation with a noncompliant balloon.

6 an the rate with angioplasty with a standard balloon.

7 percutaneous transluminal angioplasty (PTA) balloon.

8 ucted from fixed location towers or tethered balloons.

9 accomplished using ultra-high-pressure (UHP) balloons.

10 include drug-eluting stents and drug-coated balloons.

11 with much more sophistication than inflating balloons.

12 terpart of transient apical left ventricular ballooning.

13 xane formation had no effect on synchrony or ballooning.

14 ular mechanisms underlying platelet membrane ballooning.

15 .32 [0.20-0.49]), paclitaxel-eluting cutting balloon (0.054 [0.0017-0.5]), paclitaxel-eluting stent (

16 val], 0.13 [0.048-0.35]), paclitaxel-eluting balloon (0.32 [0.20-0.49]), paclitaxel-eluting cutting b

17 on angioplasty is not different from cutting balloon (0.73 [0.31-1.5]), excimer laser (0.89 [0.29-2.7

18 An angioplasty balloon (1.5-2x6 mm) was used to deliver 1 to 4 cc of 98

19 reated 7 months after pPCI with drug-eluting balloon), 1 stent thrombosis (treated 2 weeks after pPCI

20 fit to adding a scintillating crystal to the balloon: 1.65 x 10(2) +/- 4.07 x 10(1) vs. 4.44 x 10(1)

21 l Paclitaxel-Coated Percutaneous Angioplasty Balloon), 300 symptomatic patients (Rutherford class 2-4

22 l of 3,726 patients who underwent TAVR using balloon (57%) or self-expandable (43%) valves.

23 - 0.8; P = 0.014) and presence of hepatocyte ballooning (60.9% vs. 73.4%; P = 0.045).

24 (222 patients, 254 lesions) or uncoated PTA balloon (72 patients, 79 lesions) after successful predi

25 (5 patients) or a vascular or an esophageal balloon (8 patients) was ultimately successful.

26 trix task (an ethical decision task) and the balloon analog risk task (BART; a risk-taking task), and

27 e used event-related potentials (ERP) with a balloon analogue risk task (BART) paradigm to examine th

28 vity of prefrontal activation to risk in the Balloon Analogue Risk Task (BART).

29 safety events was 83.9% with the drug-coated balloon and 79.0% with standard angioplasty (P=0.005 for

30 In addition, both the outer balloon and inner capsule are designed to be soft and ch

31 eluting stent, or paclitaxel-eluting cutting balloon and paclitaxel-eluting balloon should be preferr

32 hermal ablation depends on the distance from balloon and peri-balloon blood flow leaks.

33 ound the balloon had a warming effect on the balloon and tissue temperature profiles.

34 sulin resistance, progressive hepatocellular ballooning and microvesicular steatosis.

35 Ballooning and procoagulant spreading of platelets are d

36 Ballooning and/or inflammation at liver biopsy were asso

37 tents who underwent stent fracture using UHP balloons and control patients who underwent UHP redilati

38 m (ER) enlarges and cell body asymmetrically balloons and finally ruptures.

39 cal severity of liver disease (inflammation, ballooning, and fibrosis) was not associated with the am

40 scatheter aortic valve replacement with both balloon- and self-expandable prostheses that were not st

41 and anatomy suitable for treatment with both balloon- and self-expandable transcatheter heart valves

42 r restenosis after intervention using either balloon angioplasty (BA) alone or BA with stenting.

43 ions were randomized to treatment with plain balloon angioplasty (BA) followed by PEB angioplasty and

44 Balloon angioplasty and stenting are the mainstays of en

45 Balloon angioplasty and stenting form the backbone of en

46 presented a major advancement over plain old balloon angioplasty in the management of coronary artery

47 Common carotid artery (CCA) balloon angioplasty injury was performed in rats.

48 Balloon angioplasty is inferior to all drug-eluting trea

49 Balloon angioplasty is not different from cutting balloo

50 Intentional fracture with UHP balloon angioplasty may be considered when treating sten

51 vascular response to injury in a rat carotid balloon angioplasty model.

52 The patient underwent balloon angioplasty of the stenotic SVC segment with res

53 rs of increased all-cause mortality included balloon angioplasty or bare-metal stent placement compar

54 is small series, PA stent fracture using UHP balloon angioplasty was feasible and did not result in m

55 Balloon angioplasty was limited by unpredictable procedu

56 metal stents, -24.2% (-32.2 to -16.4) versus balloon angioplasty, and -31.8% (-44.8 to -18.6) versus

57 Compared with balloon angioplasty, everolimus-eluting stent (hazard ra

58 ibition of IH in various animal models (e.g. balloon angioplasty, wire injury, and vein graft), but v

59 s having potential advantages over TAVR with balloon aortic valve predilatation (BAVP) in reducing pr

60 eplacement (TAVR) led to renewed interest in balloon aortic valvuloplasty (BAV).

61 r stent redilation of the ductus arteriosus, balloon aortic valvuloplasty, and stenting or angioplast

62 harge patients had experienced less previous balloon aortic valvuloplasty, had higher left ventricula

63 to standard treatment, which often included balloon aortic valvuloplasty.

64 s indicated that use of the BVS, female sex, balloon-artery ratio >1.25, expansion index >/=0.8, prev

65 denervation that had dissection by OCT, the balloon/artery ratio was higher (1.24 [1.17-1.32] versus

66 sections by OCT was associated with a higher balloon/artery ratio.

67 t an order of magnitude, higher than on the "balloon." Assembly of intrinsic tenase on liposomes with

68 Balloon-assisted enteroscopy allows therapeutic endoscop

69 suspected biliary tract pathology underwent balloon-assisted enteroscopy in a tertiary-care center.

70 Inner balloon, balloon surface, and tissue temperatures were m

71 rvation with 5 different systems, 3 of which balloon-based (Paradise [n=5], Oneshot [n=6], and Vessix

72 wever, different patterns were identified in balloon-based and in nonballoon-based denervation system

73 the renal arteries of patients treated with balloon-based and nonballoon-based denervation systems b

74 factors involved in the successful design of balloon-based delivery systems, including drug release k

75 In arteries treated with balloon-based denervation that had dissection by OCT, th

76 Balloon-based drug delivery systems allow localized appl

77 Challenges in the development of balloon-based drug delivery to the arterial wall include

78 epends on the distance from balloon and peri-balloon blood flow leaks.

79 a high altitude platform such as a plane or balloon, but possibly could be attempted on a lander.

80 c valve fracture (BVF) using a high-pressure balloon can be performed to facilitate VIV TAVR.

81 ing degrees of stenosis were induced using a balloon catheter in the proximal left anterior descendin

82 lymer, does not fracture when crimped onto a balloon catheter or during deployment in the artery.

83 The balloon catheter system allows homogenous drug delivery

84 The role of balloon catheters in this patient population remains ill

85 ons, although paclitaxel is the only drug on balloon catheters with proven inhibition of restenosis.

86 e resected MAP(+) areas contained mainly non-balloon-cell focal cortical dysplasia (FCD).

87 In some FCD subtypes, balloon cells express proteins typically seen in neurogl

88 nd HPV16 E6 has been described to persist in balloon cells obtained from surgical FCDIIb specimens.

89 epitope showed weak labeling of cytoplasm in balloon cells, as previously described in FCDIIb, but al

90 and maturation, impaired by the presence of balloon cells.

91 >/=35, fasting glucose >5.5 mmol/L, and many ballooned cells, NAS scores decreased significantly with

92 Optimization of the balloon coating matrix is essential for efficient drug t

93 , also showed a marked reduction in membrane ballooning, consistent with a role for chloride entry in

94 tion between hospital performance on door-to-balloon (D2B) time for STEMI and door-to-needle (DTN) ti

95 Recent reductions in average door-to-balloon (D2B) times have not been associated with decrea

96 blockers, acute reperfusion therapy, door-to-balloon [D2B] time </=90 min, and time to fibrinolysis <

97 pare success and complication rate of double-balloon (DBE) and single-balloon enteroscope (SBE) to pe

98 Studies assessing drug-coated balloons (DCB) for the treatment of femoropopliteal arte

99 0% (95% CI -15.8 to -2.2) versus drug-coated balloons (DCB), -9.4% (-17.4 to -1.4) versus sirolimus-e

100 Drug-coated balloons (DCBs) are a predominant revascularization ther

101 eported favorable outcomes using drug-coated balloons (DCBs) for treatment of symptomatic peripheral

102 Drug-coated balloons (DCBs) have shown promise in improving the outc

103 porting long-term outcomes using drug-coated balloons (DCBs) is limited.

104 ted the comparative efficacy of drug-eluting balloons (DEB) and everolimus-eluting stents (EES) in pa

105 for 25% of body weight and showed continued balloon degeneration in addition to inflammation, fibros

106 lipid peroxidation, histological evidence of balloon degeneration, and elevated serum alanine aminotr

107 itamin E, TZDs, and obeticholic acid improve ballooning degeneration in patients with NASH.

108 tage; secondary outcomes were improvement in ballooning degeneration, lobular inflammation, and steat

109 Drug-coated angioplasty balloons deliver antiproliferative agents directly to th

110 Drug-coated balloon delivery system is characterized by a rapid drug

111 In balloon denervation, the presence of dissections by OCT

112 bserved in nonballoon denervation but not in balloon denervation.

113 Dilatation pressure and balloon diameter at the highest pressure during implanta

114 femoropopliteal arterial segments and larger balloon diameters for the tibial arteries.

115 s to identify and select relevant studies of balloon dilatation and stenting for aortic coarctation b

116 fectiveness and comparative effectiveness of balloon dilatation and stenting for aortic coarctation.

117 dds of achieving </=20 mm Hg were lower with balloon dilatation as compared with stenting (odds ratio

118 Numerically more patients undergoing balloon dilatation experienced severe complications duri

119 cluded 15 stenting (423 participants) and 12 balloon dilatation studies (361 participants), including

120 uding 57 stenting (3397 participants) and 62 balloon dilatation studies (4331 participants).

121 nd 66.5% (44.1-88.9%) of patients undergoing balloon dilatation, and in 99.5% (97.5-100.0%) and 93.8%

122 nt thrombosis (treated 2 weeks after pPCI by balloon dilatation-this patient stopped all medications

123 f a relevant pressure gradient compared with balloon dilatation.

124 tomy (PS) combined with endoscopic papillary balloon dilation (EPBD) for CBD stone removal in patient

125 doscopic sphincterotomy/endoscopic papillary balloon dilation (EST/EPBD) with negative ERC finding.

126 ageal echocardiography, underwent additional balloon dilation to correct aortic regurgitation.

127 n occurred in 20 patients in whom additional balloon dilation was successful but did not occur in the

128 Results Balloon dilation was technically successful in all 52 st

129 used for MR imaging-guided catheterization, balloon dilation, and stent implantation into aorto-ilia

130 wall surface, intended to correspond to the balloon dilation-induced vascular injury and healing pro

131 ese lesions were biopsied and dilated with a balloon dilator.

132 Various sirolimus-coated balloons effectively reduce neointimal proliferation in

133 In this study, we developed a scintillating balloon-enabled fiber-optic radionuclide imaging (SBRI)

134 tractility was monitored by intraventricular balloon, energetics by (31)P nuclear MR spectroscopy, la

135 tion rate of double-balloon (DBE) and single-balloon enteroscope (SBE) to perform ERCP in Roux-en-Y p

136 Paclitaxel-eluting cutting balloon, everolimus-eluting stent, and paclitaxel-elutin

137 .6% self-expanding covered stents, and 11.2% balloon expandable bare metal stents) were placed in 692

138 the use of local anesthesia, implantation of balloon expandable device, avoidance of urinary catheter

139 Overall 898 chimney grafts (49.2% balloon expandable, 39.6% self-expanding covered stents,

140 Balloon, expandable, cobalt-chrome covered stent (Jotec,

141 31 consecutive patients undergoing TAVR with balloon-expandable (58%) or self-expandable (42%) valves

142 rmed in 20 patients undergoing VIV TAVR with balloon-expandable (n=8) or self-expanding (n=12) transc

143 ortic stenosis to either SAVR or TAVR with a balloon-expandable bovine pericardial tissue valve by ei

144 oston Scientific Lotus valve (Lotus) and the balloon-expandable Edwards Sapien 3 (ES3) valve.

145 follow-up were observed in 4 patients in the balloon-expandable group (3.4% vs. 0%; p = 0.12); all we

146 al valves to facilitate VIV TAVR with either balloon-expandable or self-expanding transcatheter valve

147 The new balloon-expandable Sapien 3 transcatheter heart valve (S

148 (TAVR) have been based primarily on a single balloon-expandable system.

149 The use of the new generation S3 balloon-expandable THV reduced the risk of more than mil

150 eart valve (Symetis ACURATE neo, n=129) or a balloon-expandable transcatheter heart valve (Edwards SA

151 The use of a balloon-expandable transcatheter heart valve previously

152 f PVR following TAVR with a third-generation balloon-expandable transcatheter heart valve.

153 rmine the midterm hemodynamic performance of balloon-expandable transcatheter heart valves.

154 r postprocedural gradients in both self- and balloon-expandable transcatheter valves.

155 Transseptal access and the balloon-expandable valve were used in 33.1% and 89.9%, r

156 pite the higher device success rate with the balloon-expandable valve, 1-year follow-up of patients i

157 Since the introduction of the first balloon-expandable valves for stenotic lesions with impl

158 Valve type (balloon-expandable vs. self-expandable, p = 0.26) and ap

159 The balloon-expandable, stainless steel, hourglass-shaped, c

160 al evacuation pattern on manometry, abnormal balloon expulsion test or impaired rectal evacuation by

161 ts received target lumen reentry by means of balloon fenestration of the aortic dissection flap.

162 nificantly higher than for that with the non-balloon guide catheter (63.7% [65 of 102] vs 35.8% [29 o

163 sing the balloon guide catheter than the non-balloon guide catheter (median, 20.5 minutes vs 41.0 min

164 d terminus by using a stent retriever with a balloon guide catheter (n = 102) at one center and a non

165 e catheter (n = 102) at one center and a non-balloon guide catheter (n = 81) at the other center.

166 ersus 67.9% (55 of 81) achieved with the non-balloon guide catheter (P = .0004).

167 The use of a balloon guide catheter during endovascular procedures sh

168 acute ischemic stroke, performed by using a balloon guide catheter or non-balloon guide catheter.

169 ation was significantly shorter by using the balloon guide catheter than the non-balloon guide cathet

170 Results Successful recanalization with the balloon guide catheter was achieved in 89.2% of thrombec

171 The one-pass thrombectomy rate with the balloon guide catheter was significantly higher than for

172 roved when performed in combination with the balloon guide catheter.

173 med by using a balloon guide catheter or non-balloon guide catheter.

174 In addition, blood flow leaks around the balloon had a warming effect on the balloon and tissue t

175 e treatment effect compared with an uncoated balloon has differed greatly among the randomized trials

176 Neointimal inhibition by limus-coated balloons has been shown in few animal studies, but data

177 olimus-eluting stent, and paclitaxel-eluting balloon have the highest probability of being in the top

178 such as drug-eluting stents and drug-coated balloons have improved patency for moderate-length lesio

179 ch Perfusion (SAAP) combines thoracic aortic balloon hemorrhage control with intra-aortic oxygenated

180 d generalized hepatitis with the presence of ballooned hepatocytes and evidence of fibrosis.

181 Hedgehog (Hh) ligand production by ballooned hepatocytes drives nonalcoholic steatohepatiti

182 Ballooned hepatocytes were quantified by keratin 8/18 an

183 eatohepatitis reminiscent of human NASH with ballooning hepatocytes and significant liver fibrosis.

184 nts, PN displacement was not possible with a balloon; however, a steerable sheath/catheter combinatio

185 Although conventional Intragastric Balloons (IGBs) have become an efficient and less invasi

186 he novelty of this system is a scintillating balloon in the front of the wide-angle lens to image lig

187 hin an aggregate, multiple platelets undergo ballooning in a synchronised fashion, dependent upon ext

188 c confocal microscopy we visualised membrane ballooning in human platelet aggregates adherent to coll

189 l that in aggregates of platelets in plasma, ballooning in multiple platelets occurs in a synchronise

190 s (provisional 97%, culotte 94%) and kissing balloon inflation (provisional 95%, culotte 98%) were hi

191 registry demonstrates that the time to first balloon inflation is slightly longer with radial access

192 magnetic soft capsule device with gas-filled balloon inflation.

193 nitrite (1.8 mumol) or NaCl (placebo) before balloon inflation.

194 catheterization laboratory and time of first balloon inflation.

195 ilitate adherence and release of drug during balloon inflation.

196 0/10 min r-I/R by percutaneous intracoronary balloon inflation/deflation in the mid left anterior des

197 Homer1 expression levels are upregulated in balloon-injured vs. uninjured VSMCs.

198 Consistent with these observations, balloon injury (BI) induced p115 RhoGEF tyrosine phospho

199 s was induced in rabbits (n=31) using aortic balloon injury and high-cholesterol diet.

200 CaMKIIgamma protein decreased 90% 14 d after balloon injury in rat carotid artery.

201 aque in rats feeding with high fat diet plus balloon injury.

202 A prototype of the proposed capsule and balloon is given.

203 The balloon is made from a thin and biocompatible material t

204 Apical ballooning is broadly recognized as the classic form of

205 We reveal that ballooning is mechanistically and structurally distinct

206 Human platelet transformation into balloons is part of the haemostatic response and thrombu

207 largely prevented synchrony without blocking ballooning itself.

208 to compare efficacy and safety of the laser balloon (LB) with wide-area circumferential pulmonary ve

209 tive tissue cooling spread radially from the balloon-left atrium-PV contact point.

210 ombs anchored in rigid confinement underwent balloon-like blowing up, allowing for dense clusters via

211 balloon than in the 28-mm cryoballoon (inner balloon, median [range]: -51.5 [-66.0 to -31.0] versus -

212 ronary artery (RCA) and left coronary artery balloon occlusion at baseline before and at follow-up ex

213 transseptal sheath (8 patients) or through a balloon occlusion catheter placed through the sheath (10

214 Animals undergoing micro-catheter or balloon occlusion demonstrated more profound hemiparesis

215 Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) at the thoracic a

216 Resuscitative endovascular balloon occlusion of the aorta (REBOA) is an innovative

217 Ischemia/reperfusion was induced in pigs by balloon occlusion of the left anterior descending artery

218 nts with paired measurements 30 minutes post balloon occlusion, LV dP/dtmax decreased from 1437.1+/-1

219 s induced by left anterior descending artery balloon occlusion.

220 d again 30 minutes after a 1-minute coronary balloon occlusion.

221 y was unchanged, indicating LV stunning post balloon occlusion.

222 nditioning performed as 4 repeated 30-second balloon occlusions followed by 30 seconds of reperfusion

223 avity expands by inversion of the tongue and ballooning of the adjacent floor of the mouth into the c

224 per unit surface area is kept constant along balloons of different lengths.

225 es, with drug-eluting stents and drug-coated balloons offering low rates of repeat revascularization.

226 ions to angioplasty with a paclitaxel-coated balloon or to standard angioplasty.

227 deployed focal therapy probe surfaces (i.e. balloons or catheters).

228 partial r(2) = 0.75, P < 0.0001), hepatocyte ballooning (P = 0.004), the ductular reaction (i.e., num

229 udy of the Stellarex Drug-Coated Angioplasty Balloon), paclitaxel plasma concentrations were measured

230 Paclitaxel-eluting balloon (PEB) angioplasty, stenting, and directional ath

231 o compare the efficacy of paclitaxel-eluting balloon (PEB) catheters and everolimus-eluting stents (E

232 ized study of mature accesses that underwent balloon percutaneous transluminal angioplasty (PTA) betw

233 Balloon placement was often difficult requiring manipula

234 ter VIV TAVR by inflation of a high-pressure balloon positioned across the valve ring during rapid ve

235 The use of balloon post-dilation tended to be associated with a hig

236 ion of Na(+), Cl(-), or water entry impaired ballooning, procoagulant spreading, and microparticle ge

237 was a greater requirement for, intra-aortic balloon pump (50% vs 15%, P < 0.01), mechanical support

238 mortality when compared with an intra-aortic balloon pump (IABP) in patients with severe shock compli

239 ched for any literature linking intra-aortic balloon pump and/or venoarterial extracorporeal membrane

240 eal membrane oxygenation due to intra-aortic balloon pump being in situ, and possible thromboembolic

241 ly revascularization and use of intra-aortic balloon pump counterpulsation therapy, the prognosis of

242 mercially available devices-the intra-aortic balloon pump counterpulsation, the Impella system, the T

243 s refractory to vasopressors or intra-aortic balloon pump counterpulsation.

244 derived from the IABP-SHOCK II (Intraaortic Balloon Pump in Cardiogenic Shock) trial.

245 e in our ICU (67% of them had an intraaortic balloon pump to unload the left ventricle).

246 Intra-aortic balloon pump was inserted, and peripheral veno-arterial

247 ive resuscitation, ventilation, intra-aortic balloon pump, and extracorporeal membrane oxygenation su

248 cluded the following: age, sex, intra-aortic balloon pump, glycoprotein IIb/IIIa inhibitors, chronic

249 Compared with intra-aortic balloon pump, Impella provides greater hemodynamic suppo

250 operative use of beta-blockers, intra-aortic balloon pump, or catecholamines.

251 gests a causal relation between intra-aortic balloon pump, veno-arterial extracorporeal membrane oxyg

252 -AMI patients had pre-operative intra-aortic balloon pumps (57.6% vs. 25.3%; p < 0.01), intubation (5

253 ker with apoptosis and liver damage, such as ballooning (r = 0.65; P < 0.001), followed by lobular in

254 noted fluoroscopically when the waist of the balloon released and by a sudden drop in inflation press

255 aneurysms, methods like intracranial stents, balloon remodelling, the double microcatheter and the mi

256 ssion in their tracheal fluid at the time of balloon removal.

257 e mechanism underlying synchronised membrane ballooning requires thrombin generation acting effective

258 luminal angioplasty with a paclitaxel-coated balloon resulted in a rate of primary patency at 12 mont

259 intrahepatic portosystemic shunt placement, balloon retrograde transvenous obliteration, and islet c

260 , which allows blood to flow into a sac or a ballooned section.

261 model was implemented by using an inflatable balloon secured around the left coronary artery.

262 uting cutting balloon and paclitaxel-eluting balloon should be preferred for treating ISR.

263 blation characteristics of freezing time and balloon size using second generation cryoballoon are sti

264 In addition, larger balloon-sized ASD diameter, Amplatzer septal occluder de

265 r operating characteristics curves to detect ballooning, steatosis, or steatohepatitis (SH) were slig

266 Inner balloon, balloon surface, and tissue temperatures were monitored

267 s -43.0 [-64.0 to -26.0] degrees C, P<0.001; balloon surface: -43.0 [-60.0 to -15.8] versus -6.5 [-46

268 ying the mechanism of presentation of apical ballooning syndrome with various chemotherapeutic agents

269 ore frequent in the esophageal stent than in balloon tamponade group (66% vs. 20%; P = 0.025).

270 l aimed at comparing esophageal stent versus balloon tamponade in patients with cirrhosis and EVB ref

271 ts have greater efficacy with less SAEs than balloon tamponade in the control of EVB in treatment fai

272 Balloon tamponade is recommended only as a "bridge" to d

273 may be an effective and safer alternative to balloon tamponade.

274 ammation (taurolithocholate), and hepatocyte ballooning (taurocholate).

275 core matching, the median vascular access-to-balloon time was 4 to 6 minutes shorter with a culprit-v

276 significant reduction in vascular access-to-balloon time, although the 4- to 6-minute difference is

277 th lab had significantly lower first door-to-balloon times (median 191 versus 116 minutes, P<0.0001).

278 Median door-to-balloon times in the hypothermia and control groups were

279 Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis and Maintain Vessel Patenc

280 d utilized a micro-catheter or an inflatable balloon to occlude the M1 segment in six monkeys.

281 tely, the kidney transplant waiting list has ballooned to over 100,000 Americans.

282 Drugs are coated onto balloons using excipients as drug carriers to facilitate

283 ng scaffold-solvent approach while the outer balloon utilizes a novel fabrication approach for 3D sph

284 s symptomatic before pregnancy and underwent balloon valvotomy.

285 g transcatheter aortic valve implantation or balloon valvuloplasty.

286 patients, TAVI was performed without aortic balloon valvuloplasty.

287 t of Drug-Eluting Stents: Paclitaxel-Eluting Balloon vs Everolimus-Eluting Stent) and RIBS V (Resteno

288 ent of Bare Metal Stents: Paclitaxel-Eluting Balloon vs Everolimus-Eluting Stent) randomized trials w

289 The median balloon:waist ratio was 1.17 (1-1.71), and the median in

290 cardiac catheterization laboratory to first balloon was 27 minutes (25th%-75th%, 21-34) for the femo

291 scintillating crystal (500 mum thick) to the balloon was also investigated.

292 nce of PN capture was achieved only once the balloon was directly over the ablation catheter.

293 The drug-coated balloon was noninferior to the standard balloon with res

294 The scintillating balloon was then fabricated from 10 mL of silicone RTV c

295 Importantly, synchronised ballooning was closely followed by a surge in microvesic

296 Hepatocellular ballooning was reduced in 84.2% of samples (n = 69; 95%

297 timal M30 cut-off values for mild and severe ballooning were 330 and 420 U/L, and 290 and 330 U/L for

298 A corresponding effect on hepatocyte ballooning were also noted.

299 ated balloon was noninferior to the standard balloon with respect to safety.

300 ally with thrombin plus collagen, are large "balloons" with a small ( approximately 1 mum radius) "ca